The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 26, 2013
Filed:
Jan. 19, 2006
Joe W. Gray, San Francisco, CA (US);
Yinghui Guan, South San Francisco, CA (US);
Wen-lin Kuo, San Ramon, CA (US);
Jane Fridlyand, San Francisco, CA (US);
Gordon B. Mills, Houston, TX (US);
Joe W. Gray, San Francisco, CA (US);
Yinghui Guan, South San Francisco, CA (US);
Wen-Lin Kuo, San Ramon, CA (US);
Jane Fridlyand, San Francisco, CA (US);
Gordon B. Mills, Houston, TX (US);
The Regents of the University of California, Oakland, CA (US);
The Board of Regents, University of Texas System, Austin, TX (US);
Abstract
Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.